Vir Biotechnology (VIR) Payables (2018 - 2026)
Vir Biotechnology (VIR) posted Payables of $5.4 million for Q1 2026, down 44.46% sequentially from $9.8 million in Q4 2025, and up 46.17% YoY from $3.7 million in Q1 2025.
Vir Biotechnology (VIR) Payables (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Payables for 9 years, with the latest figure at $5.4 million in Q1 2026.
- Quarterly Payables rose 46.17% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (up 46.17% YoY) and the FY2025 annual result came in at $9.8 million, up 92.93% from the prior year.
- Payables eased to $5.4 million in Q1 2026 per VIR's latest filing, from $9.8 million in the prior quarter.
- Over five years, Payables peaked at $12.4 million in Q2 2023 and troughed at $2.7 million in Q3 2022.
- A 5-year average of $7.5 million and a median of $6.8 million in 2025 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2024: Payables surged 196.0% in 2022, then sank 64.5% in 2024.
- Over 5 years, Payables stood at $6.4 million in 2022, then declined by 1.37% to $6.3 million in 2023, then slipped by 19.78% to $5.1 million in 2024, then surged by 92.93% to $9.8 million in 2025, then sank by 44.46% to $5.4 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $5.4 million, $9.8 million, and $6.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 17.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.75 Mn |
| Mar 31, 2026 | 5.45 Mn |
| Dec 31, 2025 | 9.80 Mn |
| Sep 30, 2025 | 6.85 Mn |
| Jun 30, 2025 | 12.23 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | 5.08 Mn |
| Sep 30, 2024 | 7.31 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Mar 31, 2024 | 7.11 Mn |
| Dec 31, 2023 | 6.33 Mn |
| Sep 30, 2023 | 3.63 Mn |
| Jun 30, 2023 | 12.36 Mn |
| Mar 31, 2023 | 12.15 Mn |
| Dec 31, 2022 | 6.42 Mn |
| Sep 30, 2022 | 2.72 Mn |
| Jun 30, 2022 | 10.62 Mn |
| Mar 31, 2022 | 10.96 Mn |
| Dec 31, 2021 | 6.52 Mn |
| Sep 30, 2021 | 4.23 Mn |